Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Highlights * Total revenue of $64.1 million, a 48% increase year-over-year * Gross margin of 83.0%, non-GAAP gross margin of 83.3% * Net operating loss of $17.9 million; non-GAAP net operating loss of $7.9 million 2026 Annual Guidance * Total revenue of $246 million to $250 million (approximately 40% to 42% growth year-over-year), compared to previous guidance of $228 million to $232 million (approximately 29% to 32% growth year-over-year) * Non-GAAP gross margin of approximately 82%, compared to previous guidance of approximately 81% "The second quarter reflects the growing strength of Heartflow's category leadership and unique AI technology platform for identifying, diagnosing, managing and treating coronary artery disease," said John Farquhar, President and CEO of Heartflow. "The CCTA market for detecting CAD continues to grow rapidly and remains significantly under-penetrated, providing a strong backdrop for continued growth. Our FFR(CT) business remains strong and durable, while Plaque is rapidly emerging as a meaningful second growth engine — helping us win new accounts, deepen physician utilization and expand the value of the Heartflow platform for our customers. At the same time, record gross margin and improving operating leverage demonstrate the increasing scalability of our model, giving us greater confidence in long-term, profitable growth."